Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Press Releases

Latest Press Releases

•	MSF logistician, Athanasios Papadopoulos holding a sign advocating for broader use of the pneumonia vaccine at a lower price Anna Pantelia
Press release
Press release |
12 April 2019
Vaccines
EuropeGreece

Greece: MSF uses ‘Humanitarian Mechanism’ for first time in Europe due to high price of pneumonia vaccine

5 min
Press release |
20 February 2019
Intellectual property and trade
United States of America

Novartis secures FDA innovation prize for 30-year-old drug

4 min
XDR-TB patient Nischaya, at home the Ambedkar Nagar area of Mumbai, with her TB medication. Photography by Atul Loke
Press release
Press release |
07 February 2019
Tuberculosis
India

TB activists for first time challenge TB drug patent in India

6 min
Iryna Shchyra, deputy head of the pharmacy at the Zhytomyr Regional TB Dispensary, holds a bottle of bedaquiline. Photo credit: Oksana Parafeniuk
Press release
Press release |
22 December 2018
Tuberculosis

As WHO issues new TB treatment guidelines, MSF calls for urgent scale-up of all-oral treatment

4 min
In March 2017, organisations from 17 European countries filed an opposition to Gilead Science's patent on the highly effective hepatitis C drug sofosbuvir. On 13th and 14th of September 2018, the hearing took e place before the European Patent Office in Munich.  Activists held a protest in front of the European Patent Office for affordable medicines at the start of proceedings on 13 September. Photograph by Peter Bauza
Press release
Press release |
05 December 2018
Hepatitis C
Europe

Health groups appeal European Patent Office decision to uphold Gilead’s patent on hepatitis C drug

3 min
Mbulumbuzi Health Centre. Adolescent HIV project. Patients perform a dance to start the "six-months-meeting day" in which the supporting staff welcome new members and monitor all the girls and boy who already joined the program. Photograph by Luca Sola
Press release
Press release |
29 November 2018
HIV/AIDS

Pharmaceutical corporations failing children with HIV

4 min
Din Savorn, 50, displays his pill carrying case while he waits for his appointment at the MSF Hepatitis C clinic at Preah Kossamak Hospital in Phnom Penh, Cambodia, 20, April 2017. Photograph by Todd Brown
Press release
Press release |
14 November 2018
Hepatitis C
China

MSF challenges unmerited patent for lifesaving hepatitis C medicine in China

4 min
Photograph by Siddharth Singh Photograph by Siddharth Singh

IP RCEP protest in India.

Press release
Press release |
13 November 2018
Intellectual property and trade

RCEP trade agreement negotiations update and statement

3 min
  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury